Orakl Oncology Raises $34 Million Series A for AI Cancer Drug Prediction
Orakl Oncology raised an oversubscribed $34 million Series A co-led by Norrsken VC and Singular, bringing its total funding to $50 million. The proceeds will support broader cancer coverage, increased data generation and deployment across more than 10 drug programs.
- Raised
- $34 million
- Round
- Series A
- Investors
- 10
- Investors
- Norrsken VCSingularInfraViaSerenaPatient Autonome Fund managed by Bpifranceteampact.venturesPlug and PlayVerve VenturesSpeedinvestHCVC
- Target market
- Biopharmaceutical companies developing cancer drugs
- Use of funds
- Expand the dataset and AI research team, increase data generation fivefold, extend into lung and gastric cancers, establish US and UK teams, deploy predictions across more than 10 drug programs, and discover and validate drug co-targets from patient biology and experimental screens
Get started
Create a free account to read the full story.
Quick Answers
What is the latest news about Orakl Oncology?
Orakl Oncology raised an oversubscribed $34 million Series A co-led by Norrsken VC and Singular, bringing its total funding to $50 million. The proceeds will support broader cancer coverage, increased data generation and deployment across more than 10 drug programs.
What does Orakl Oncology do?
Orakl Oncology was founded in 2023 as a spin-out of Gustave Roussy. Its co-founders are CEO Fanny Jaulin, CTO Gustave Ronteix and COO Diane-Laure Pagès.
How much did Orakl Oncology raise?
Orakl Oncology raised $34 million in its Series A.
Who invested in Orakl Oncology?
Investors named in this Series A include Norrsken VC, Singular, InfraVia, Serena, Patient Autonome Fund managed by Bpifrance, teampact.ventures, Plug and Play and Verve Ventures and 2 others.
How will Orakl Oncology use the funding?
Orakl Oncology plans to use the money for expand the dataset and AI research team, increase data generation fivefold, extend into lung and gastric cancers, establish US and UK teams, deploy predictions across more than 10 drug programs, and discover and validate drug co-targets from patient biology and experimental screens.
Where is Orakl Oncology based?
Orakl Oncology is based in Paris.
Who are the key people at Orakl Oncology?
Key people named in this report: Fanny Jaulin (CEO and Co-Founder), Gustave Ronteix (CTO & Co-Founder) and Diane-Laure Pagès (COO & Co-Founder).